GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding a press release dated 0 , , titled "Press release ".
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GSK India reported full year revenue of INR 3790 crores, up 2%, and Profit After Tax of INR 1012 crores, up 10%. EBITDA margins expanded by 290 basis points to 34%. The Board recommended a final dividend of Rs. 57 per equity share. For Q4 standalone, revenue was INR 989 crores with PAT of INR 275 crores. Supply chain disruptions constrained topline growth during the year. The company received market authorisation for Blenrep (anti-BCMA ADC therapy) for relapsed or refractory multiple myeloma. Oncology portfolio led by Jemperli and Zejula is tracking strongly with Jemperli receiving first-line approval for primary advanced and recurrent endometrial cancer.
Strong profitability and margin expansion demonstrate operational efficiency despite supply chain headwinds. New oncology approvals and pipeline progress signal innovation-led growth strategy, which could support re-rating of the stock.